# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company, today announced that it entered i...
Stifel analyst Thomas Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $110 to $130.
Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price target from $110 to...
Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $120 to $130.
Jefferies analyst Michael Sarcone upgrades Glaukos (NYSE:GKOS) from Hold to Buy and raises the price target from $84 to $125.
Glaukos reports Q1 adjusted EPS loss, sales beat estimates. Strong guidance for 2024 with positive analyst sentiment, driving s...
BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target from $107 to $112.
JP Morgan analyst Allen Gong maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price target from $108 to $110.